Multiomic Selection of Cancer-Testis Antigens as Precision Immuno-oncologic Targets in Head and Neck Cancer

Can cancer-testis antigens (CTAs) be leveraged as precision immuno-oncologic targets for head and neck cancer?In this cross-sectional study including 33 samples from patients with head and neck squamous cell carcinoma (HNSCC), 23 testis-restricted and 44 testis-selective CTAs with tumor-specific expression were identified in both de novo and radiation-recurrent HNSCCs, validated across transcriptomic, genomic, and proteomic analyses. Of these, a core set of 14 CTAs were consistently detected across all datasets analyzed.The CTAs identified in this study in both de novo and recurrent HNSCCs represent potential precision immuno-oncologic targets for adoptive cell therapeutics, such as T-cell receptor–engineered T-cell therapy.

Corresponding Author: Joseph Zenga, MD, Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 (jyzenga@mcw.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.